Online inquiry

IVTScrip™ mRNA-Anti-TNFSF13B, A-623(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ722MR)

This product GTTS-WQ722MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets TNFSF13B gene. The antibody can be applied in Systemic lupus erythematosus (SLE) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001145645.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 10673
UniProt ID Q9Y275
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFSF13B, A-623(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ722MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4703MR IVTScrip™ mRNA-Anti-MAPT, BMS-986168(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BMS-986168
GTTS-WQ14450MR IVTScrip™ mRNA-Anti-IGF1R, RO4858696-000(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA RO4858696-000
GTTS-WQ5347MR IVTScrip™ mRNA-Anti-CD38, CD38-Attenukine(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CD38-Attenukine
GTTS-WQ12529MR IVTScrip™ mRNA-Anti-PDCD1, NPVPDR001(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA NPVPDR001
GTTS-WQ8050MR IVTScrip™ mRNA-Anti-F, H1H3592P3(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA H1H3592P3
GTTS-WQ9344MR IVTScrip™ mRNA-Anti-TNFRSF18, INCAGN-01876(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA INCAGN-01876
GTTS-WQ4456MR IVTScrip™ mRNA-Anti-SLAMF7, BMS-901608(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-901608
GTTS-WQ14138MR IVTScrip™ mRNA-Anti-PCSK9, aPCSK927(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA aPCSK927
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW